Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement

CMPX +7.61%

With strong three-month performance and significant upside potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot on our list of the 12 hot penny stocks to invest in right now.

A doctor in a lab coat holding a healthcare solution in their hands.

On November 10, 2025, H.C. Wainwright’s Joseph Pantginis reiterated a “Buy” rating on Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 price target. The company’s advancing pipeline, marked by the preclinical progress of CTX-10726, gained the analyst’s confidence, who was particularly impressed with the bispecific antibody’s substantial potential. At SITC 2025, the drug demonstrated high-affinity target engagement and robust anti-tumor activity. The analyst also cited the molecule’s competitive edge over agents such as ivonescimab and bevacizumab, reinforcing optimism as its planned Phase 1 trial in 2026 comes closer.

Meanwhile, Compass Therapeutics, Inc. (NASDAQ:CMPX) reported Q3 2025 results on November 5. The cash balance reached $220 million by the end of Q3, which will support operations through 2028. G&A expenses recorded a substantial increase, growing from $8.6 million in Q3 2024 to $12.8 million. Management also reiterated its expectations to deliver overall survival (OS) and progression-free survival (PFS) data for tovecimig in late Q1 2026. This could potentially support the company’s first BLA filing in the second half of 2026. At the same time, Compass reported encouraging results in the Phase 1 study of CTX-8371. The company recorded a net loss of $14.3 million, or $0.08 per share, for the quarter.

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology company, develops antibody-based therapies targeting angiogenesis, immune activation, and tumor evasion pathways.

While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.

Disclosure: None.